Abstract
Two paclitaxel(Ptx)-resistant ovarian cancer cell lines, 1A9/Ptx-10 and 1A9/Ptx-22, isolated from the 1A9 cell line (a clone of the A2780 line) by continuous exposure to Ptx and verapamil, have point mutations in their major β-tubulin gene and in one or both alleles of their TP53 gene. These cells were examined for alterations in cell cycle regulators and the tubulin-binding protein stathmin. Unlike parental cells, neither 1A9/Ptx-10 nor 1A9/Ptx-22 expressed detectable levels of p21WAF1/Cip1, a putative transcriptional regulator of stathmin, but did overexpress stathmin and Bcl2. No differences were noted in the expression levels of proliferative cell nuclear antigen or tyrosine-phosphorylated p34Cdc2. Ptx treatment altered little the expression of stathmin in the parental cell line, although it increased p21WAF1/Cip1 levels several-fold. Infection of Ptx-resistant lines with a wild-type TP53-bearing adenovirus (AdWTp53) changed cell cycle distribution and increased the levels of p21WAF1/Cip1, but caused no changes in stathmin levels. Microtubule drug resistance in ovarian carcinoma may be associated with altered p53/21WAF1/Cip1 regulatory pathways for stathmin expression and function.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- HBSS:
-
Hank's balanced salts solution
- MOI:
-
multiplicity of infection
- MT:
-
microtubule
- PCNA:
-
proliferative cell nuclear antigen
- Ptx:
-
paclitaxel
References
Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ and George DL . (1999). Oncogene, 18, 5954–5958.
Alli E, Bash-Babula J, Yang JM and Hait WN . (2002). Cancer Res., 62, 6864–6869.
Andersen SS . (1999). BioEssays, 21, 53–60.
Andersen SS . (2000). Trends Cell Biol., 10, 261–267.
Bieche I, Lachkar S, Becette V, Cifuentes-Diaz C, Sobel A, Lidereau R and Curmi PA . (1998). Br. J. Cancer, 78, 701–709.
Brattsand G . (2000). Br. J. Cancer, 83, 311–318.
Cheon MS, Fountoulakis M, Cairns NJ, Dierssen M, Herkner K and Lubec G . (2001). J. Neural Transm. Suppl., 61, 281–288.
Curmi PA, Nogues C, Lachkar S, Carelle N, Gonthier MP, Sobel A, Lidereau R and Bieche I . (2000). Br. J. Cancer, 82, 142–150.
Di Paolo G, Pellier V, Catsicas M, Antonsson B, Catsicas S and Grenningloh G . (1996). J. Cell Biol., 133, 1383–1390.
Downing K . (2000). Annu. Rev. Cell Dev. Biol., 16, 89–111.
Friedrich B, Gronberg H, Landstrom M, Gullberg M and Bergh A . (1995). Prostate, 27, 102–109.
Gavet O, Ozon S, Manceau V, Lawler S, Curmi P and Sobel A . (1998). J. Cell Sci., 111, 3333–3346.
Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV and Fojo T . (2000). Oncogene, 19, 3078–3085.
Giannakakou P, Sackett DL, Kang YK. Zhan Z, Buters JTM, Fojo T and Poruchynsky MS . (1997). J. Biol. Chem., 272, 17118–17125.
Gradin HM, Larsson N, Marklund U and Gullberg M . (1998). J. Cell Biol., 140, 131–141.
Gu Y, Turck CW and Morgan DO . (1993). Nature, 366, 707–710.
Howell B, Deacon H and Cassimeris L . (1999). J. Cell Sci., 112, 3713–3722.
Horwitz SB, Shen HJ, He L, Dittmar P, Neef R, Chen J and Schubart UK . (1997). J. Biol. Chem., 272, 8129–8132.
Hummert TW, Schwartz Z, Sylvia VL, Dean DD, Hardin RR and Boyan BD . (2000). J. Cell. Biochem., 79, 150–163.
Iancu C, Mistry SJ, Arkin S and Atweh GF . (2000). Cancer Res., 60, 3537–3541.
Ji H, Baldwin GS, Burgess AW, Moritz RL, Ward LD and Simpson RJ . (1993). J. Biol. Chem., 268, 13396–13405.
Jimenez GS, Khan HS, Stommel JM and Wahl GM . (1999). Oncogene, 18, 7656–7665.
Johnsen JI, Aurelio ON, Kwaja Z, Jorgensen GE, Pellegata NS, Plattner R and Stanbridge EJ. Cajot JF . (2000). Int. J. Cancer, 88, 685–691.
Johnson WE, Jones NA, Rowlands, DC, Williams A, Guest SS and Brown G . (1995). FEBS Lett., 364, 309–313.
Johnsson A, Zeelenberg I, Min Y, Hilinski J, Berry C, Howell SB and Los G . (2000). Br. J. Cancer, 83, 1047–1054.
Katayose D, Gudas J, Nguyen H, Srivastava S, Cowan KH and Seth P . (1995). Clin. Cancer Res., 1, 889–897.
Larsson N, Melander H, Marklund U, Osterman R and Gullberg M . (1995). J. Biol. Chem., 270, 14175–14183.
Larsson N, Segerman B, Gradin H, Wandizioch E, Cassimeris L and Gullberg M . (1999). Mol. Cell. Biol., 19, 2242–2250.
Lawler S . (1998). Curr. Biol., 8, R212–R214.
Lewis TS, Hunt JB, Aveline LD, Hunt JB, Aveline LD, Jonscher KR, Louie DF, Yeh JM, Nahreini TS, Resing KA and Ahn NG . (2000). Mol. Cell, 6, 1343–1354.
Liedtke W, Leman EE, Fyffe REW, Raine CS and Schubart UK . (2002). Am. J. Pathol., 160, 469–480.
Marklund U, Osterman O, Melander H, Bergh A and Gullberg M . (1994). J. Biol. Chem., 269, 30626–30635.
McNally FJ . (1996). Curr. Opin. Cell Biol., 8, 23–29.
Michalak M, Corbett EF, Mesaeli N, Nakamura K and Opas M . (1999). Biochem. J., 344, 281–292.
Mistry SJ and Atweh GF . (2001). J. Biol. Chem., 276, 31209–31215.
Moreno FJ and Avila J . (1998). Mol. Cell Biochem., 183, 201–209.
Murphy M, Ahn J, Walker KK, Hoffaman WH, Evans RM, Levine AJ and George DL . (1999). Genes Dev., 13, 2490–2501.
Poruchynsky MS, Giannakakou P, Ward Y, Bulinski JC, Telford WG, Robey RW and Fojo T . (2001). Biochem. Pharmacol., 62, 1469–1480.
Price DK, Ball JR, Bahrani-Mostafavi Z, Vachris JC, Kaufman JS, Naumann RW, Higgins RV and Hal JB . (2000). Cancer Invest., 18, 722–730.
Reed JC . (1995). Curr. Opin. Oncol., 7, 541–546.
Rowlands DC, Williams A, Jones NA, Guest SS, Reynolds GM, Barber PC and Brown G . (1995). Lab. Invest., 72, 100–113.
Steinman RA, Yaroslavsky B, Kaplan SS, Goff JP and Shields DS . (2000). Leuk. Res., 24, 601–610.
Vancompernolle K, Boonefaes T, Mann M, Fiers W and Grooten J . (2000). J. Biol. Chem., 275, 33876–33882.
Walczak CE . (2000). Curr. Opin. Cell Biol., 12, 52–56.
Wallon G, Rappsilber J, Mann M and Serrano L . (2000). EMBO J., 19, 213–222.
Acknowledgements
We are grateful to Drs Tito Fojo and Paraskevi Giannakakou for providing the 1A9, 1A9/Ptx-10 and 1A9/Ptx-22 cell lines and Dr Shiv Srivastava for the generous gift of AdWTp53 and d1312 control viruses. This work was supported by a grant from the USPHS (CA 78039).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Balachandran, R., Welsh, M. & Day, B. Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells. Oncogene 22, 8924–8930 (2003). https://doi.org/10.1038/sj.onc.1207060
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207060
Keywords
This article is cited by
-
Susceptibility of cytoskeletal-associated proteins for tumor progression
Cellular and Molecular Life Sciences (2022)
-
The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients
Clinical and Translational Oncology (2016)
-
Elevated STMN1 promotes tumor growth and invasion in endometrial carcinoma
Tumor Biology (2016)
-
Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients
Clinical and Translational Oncology (2016)
-
Predictive value of STMN1 gene promoter polymorphism (−2166T>C) in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine
Cancer Chemotherapy and Pharmacology (2015)